Key points are not available for this paper at this time.
The hypothesis of this FDA-IRB approved open-label pilot trial was that patients with ASD and mt dysfunction would improve clinically and/or biochemically following treatment with a combination of carnitine, coenzyme Q10 and alpha-lipoic acid (MitoCocktail).
Legido et al. (Tue,) studied this question.